SS Innovations International
SS Innovations International's revenue rose 105.7% to $42 million in fiscal 2025. Its operating margin was −19.3%, up from −91.9% a year earlier. Free cash flow was −$22 million. The diluted share count rose 9.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
SS Innovations International lost money in fiscal 2025: a net loss of $12 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0 | 0 | 2 | 0 | 3 |
| Debt incl. finance leases | — | 1 | 0 | 8 | — |
| Net debt (negative means net cash) | — | 0 | −2 | 7 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.0x | 0.6x | — |
| Interest coverage | — | −18.3x | −38.7x | −19.5x | −7.4x |
| Current ratio | 1.4x | 0.5x | 2.5x | 1.3x | 1.9x |
| Quick ratio | 1.4x | 0.4x | 1.7x | 0.8x | 1.2x |
Cash flow
Projections
Project SS Innovations International's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $5.2 million of SS Innovations International shares on the open market, and 1 insider sold $99,999.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Srivastava SudhirChairman and CEO, Director, 10% owner | Sold | 33,333 | $3.00 | $99,999 | Form 4 |
| Mar 6, 2026 | Srivastava SudhirChairman and CEO, Director, 10% owner | Bought | 498,753 | $4.01 | $2.0 million | Form 4 |
| Mar 6, 2026 | Frederic H MollDirector, 10% owner | Bought | 501,253 | $3.99 | $2.0 million | Form 4 |
| Mar 6, 2026 | Timothy P. AdamsDirector | Bought | 300,000 | $3.99 | $1.2 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 3 of 9 | — |
| Rule of 40 | 39.9% | 202.2% | 53.5% |
| Altman Z'' | −2.41 | −4.94 | −0.08 |
| Accruals ratio | −28.7% | −26.1% | 11.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Pass | Fail | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 5 of 9 | 3 of 9 | — |
Compare
Put SS Innovations International side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| SS Innovations International | FY25 | 105.7% | −19.3% | −52.3% | — | — | — | |
| KORU Medical Systems | FY25 | 22.2% | −7.2% | −1.1% | — | — | — | Compare |
| SANUWAVE Health | FY25 | 35.0% | 11.2% | 4.4% | — | 1.7x | — | Compare |
| Myomo | FY25 | 25.7% | −35.2% | −39.7% | — | — | 3 | Compare |
| Pulsenmore | FY25 | 314.3% | — | −82.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | 1 | 6 | 21 | 42 |
| Revenue growth | — | — | — | — | — | — | — | 309.1% | 251.5% | 105.7% |
| Gross profit | — | — | — | — | — | — | 0 | 1 | 8 | 20 |
| Research and development | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 |
| Operating income | — | — | — | — | — | — | −3 | −20 | −19 | −8 |
| Net income | −0 | −1 | −1 | −3 | −1 | −2 | −3 | −21 | −19 | −12 |
| Diluted EPS (US$) | −0.03 | −0.05 | −0.05 | −0.16 | −0.05 | −0.05 | −0.03 | −0.14 | −0.11 | −0.06 |
| Diluted shares (millions) | 18 | 20 | 21 | 22 | 23 | 28 | 128 | 152 | 181 | 199 |
| Cash flow | ||||||||||
| Cash from operations | −0 | −0 | −0 | −0 | −0 | −0 | −6 | −15 | −10 | −18 |
| Capital expenditure | — | — | — | 0 | — | — | 0 | 0 | 1 | 4 |
| Free cash flow | — | — | — | −0 | — | — | −6 | −16 | −10 | −22 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 10 | 14 | 8 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 |
| Debt incl. finance leases | — | — | — | — | — | — | 1 | 0 | 8 | — |
| Total assets | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 32 | 42 | 74 |
| Total liabilities | 1 | 0 | 0 | 1 | 1 | −0 | 10 | 12 | 29 | 36 |
| Shareholders' equity | −0 | 0 | −0 | −1 | −1 | 1 | −3 | 20 | 14 | 38 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | 4.2% | 12.3% | 40.9% | 46.0% |
| Operating margin | — | — | — | — | — | — | −206.0% | −345.1% | −91.9% | −19.3% |
| Net margin | — | — | — | — | — | — | −223.8% | −355.4% | −92.7% | −28.6% |
| Free cash flow margin | — | — | — | — | — | — | −432.7% | −269.2% | −49.2% | −52.3% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | 39.9% | 202.2% | 53.5% |
| Return on capital | — | — | — | — | — | — | — | −201.5% | −77.4% | — |
| Return on equity | — | — | — | — | — | — | — | −245.1% | −115.5% | −46.9% |
| Return on assets | — | −258.7% | −293.1% | −2,436.3% | −499.4% | −397.7% | −86.8% | −108.5% | −51.8% | −20.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |